New York-Presbyterian Hospital

After three years of work, the EXaCT-1 exome cancer test has become part of clinical cancer care at NewYork-Presbyterian, but developers have higher ambitions.

The company hopes to raise funding this summer and has been conducting pilots with NewYork-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center.

The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.

The test, EXaCT-1, may not only help doctors find treatments for patients who have run out of options but may also provide biomarkers of immunotherapy response.

The Irving Institute, a CUMC partnership with New York-Presbyterian, will fund its precision medicine program and the development of new therapies.

NEW YORK (GenomeWeb News) – Weill Cornell Medical College and New York-Presbyterian Hospital have partnered to launch a new institute that will pursue genome-centered translational medicine to deliver personalized care.

In the May issue of Cancer Prevention Research, Steven Lipkin and colleagues reported that in colon cancer cell lines, the protective effect against colorectal cancer was stronger in cells with a particular SNP in the HMGCR gene.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.